https://actuatetherapeutics.com/press_releases/drs-roger-b-cohen-lee-m-ellis-and-john-l-marshalljoin-actuate-therapeutics-scientific-advisory-board/ 2024-02-28T13:06:26+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-congratulatesdr-patricia-lorusso-on-being-named-aacr-president-elect/ 2024-02-28T13:06:26+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-poster-presentations-at-the-2023-aacr-annual-meeting/ 2024-02-28T13:06:26+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announcesposter-presentations-at-the-2023-asco-annual-meeting/ 2024-02-28T13:06:26+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-receives-fda-orphan-drug-designation-for-elraglusib-for-treatment-of-pancreatic-cancer/ 2024-02-28T13:06:26+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-first-patient-enrolled-in-phase-2-clinical-trial-of-elraglusib-plus-retifanlimab-as-investigational-first-line-therapy-for-patients-with-advanced-pancreatic-cancer/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-initiation-of-a-multicenterrandomized-trial-of-elraglusib-plus-folfirinox-as-first-linetherapy-for-advanced-pancreatic-cancer/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announcesprimary-endpoint-met-in-phase-2-studyin-pancreatic-cancer/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announcesfda-fast-track-designation-for-9-ing-41for-treatment-of-pancreatic-cancer/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announcesinitiation-of-phase-2-clinical-studyin-pancreatic-cancer/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-9-ing-41-datapresentation-at-asco-annual-meeting-2020/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announcesinitiation-of-additional-clinical-studies-for-9-ing-41/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeuticscompletes-6-5-million-series-b-3-financingto-expand-clinical-programs/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeuticscompletes-21-7-million-series-b-financing/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-opens-phase-1-2-clinical-study-of-9-ing-41-in-patients-with-refractory-cancers/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-submits-ind-application-for-treatment-of-refractory-cancers/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-receives-rare-pediatric-disease-designation-for-9-ing-41-for-treatment-of-neuroblastoma/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-programs-highlightedin-clinical-cancer-research/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/dr-francis-giles-joins-actuate-therapeuticsas-chief-medical-officer/ 2024-02-28T13:06:27+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-poster-presentations-at-the-2024-aacr-annual-meeting/ 2024-04-08T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-files-registration-statement-for-initial-public-offering-2/ 2024-05-28T07:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-pricing-of-initial-public-offering/ 2024-08-12T08:27:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-closing-of-initial-public-offering/ 2024-08-14T04:05:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-ring-the-nasdaq-opening-bell-on-friday-august-23-2024/ 2024-08-20T09:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference/ 2024-09-05T09:10:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-obtains-complete-responses-and-provides-update-on-clinical-trial-of-elraglusib-for-the-treatment-of-relapsed-refractory-ewing-sarcoma/ 2024-09-09T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-receives-fda-orphan-drug-designation-for-elraglusib-for-treatment-of-soft-tissue-sarcomas/ 2024-09-11T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-announces-upcoming-presentation-on-initial-data-on-elraglusib-in-combination-with-folfirinox-at-the-aacr-special-conference-on-advances-in-pancreatic-cancer-research/ 2024-09-16T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-announces-scientific-reports-publication-on-elraglusibs-novel-immunomodulatory-mechanism-of-action-as-a-gsk-3β-inhibitor/ 2024-09-23T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-to-participate-in-lanterns-pharma-webinar-on-ai-driven-drug-development/ 2024-10-29T06:39:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-announces-fda-rare-pediatric-disease-designation-granted-to-elraglusib-for-treatment-of-ewing-sarcoma/ 2024-11-12T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-be-added-to-russell-2000-index/ 2024-11-26T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-positive-interim-phase-2-data-of-elraglusib-in-first-line-treatment-of-metastatic-pancreatic-cancer/ 2024-12-17T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-receives-ema-orphan-medicinal-product-designation-for-elraglusib-for-the-treatment-of-pancreatic-cancer/ 2025-01-07T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-participate-in-upcoming-investor-conferences-in-february/ 2025-02-06T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-announces-completion-of-enrollment-in-a-phase-2-trial-of-elraglusib-in-combination-with-folfirinox-and-losartan-in-patients-with-previously-untreated-metastatic-pancreatic-cancer/ 2025-02-25T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-to-present-promising-data-on-elraglusib-in-advanced-salivary-gland-carcinoma-at-the-aacr-annual-meeting-2025/ 2025-04-17T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-to-present-elraglusib-phase-2-topline-data-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting/ 2025-04-23T10:24:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-participate-in-citizens-life-sciences-conference-2025/ 2025-04-30T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-statistically-significant-topline-results-from-global-phase-2-trial-of-elraglusib-in-first-line-treatment-of-metastatic-pancreatic-cancer/ 2025-05-06T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-host-kol-event-on-topline-phase-2-data-of-elraglusib-in-metastatic-pancreatic-ductal-adenocarcinoma-during-asco-annual-meeting/ 2025-05-07T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-details-for-2025-asco-annual-meeting-presentation-on-topline-elraglusib-phase-2-data-in-first-line-treatment-of-metastatic-pancreatic-cancer/ 2025-05-22T05:05:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-presents-topline-elraglusib-phase-2-data-at-asco-2025-annual-meeting-trial-meets-primary-endpoint-of-median-overall-survival-and-doubles-1-year-survival-in-first-line-treatment-o/ 2025-05-31T04:30:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-shares-highlights-from-kol-event-on-positive-topline-elraglusib-phase-2-data-in-first-line-treatment-of-metastatic-pancreatic-cancer/ 2025-06-02T09:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-inclusion-in-the-russell-3000-and-russell-2000-indexes/ 2025-06-16T08:30:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-reports-positive-biomarker-and-machine-learning-data-from-phase-2-elraglusib-trial-in-first-line-treatment-of-metastatic-pancreatic-cancer-at-asco/ 2025-06-20T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-highlights-significant-and-sustained-survival-benefit-in-key-metastatic-pancreatic-cancer-patient-populations-in-phase-2-elraglusib-trial/ 2025-06-24T09:15:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-advances-clinical-program-in-ewing-sarcoma-after-positive-phase-1-trial-demonstrates-complete-and-partial-responses-in-difficult-to-treat-pediatric-sarcomas/ 2025-07-17T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-collaborate-with-incyte-corporation-and-the-university-of-pittsburgh-on-clinical-trial-of-elraglusib-in-combination-with-retifanlimab-and-mfolfirinox-in-patients-with-advanced/ 2025-08-06T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-proposed-public-offering-of-common-stock/ 2025-09-09T04:07:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-pricing-of-15-0-million-public-offering-of-common-stock/ 2025-09-10T08:31:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-closing-of-17-25-million-public-offering-of-common-stock-including-full-exercise-of-over-allotment-option/ 2025-09-11T04:01:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-provides-fda-with-updated-clinical-data-package-to-support-planned-regulatory-interactions-with-fda-and-ema-over-the-coming-months/ 2025-09-22T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-publication-of-positive-phase-ii-clinical-data-for-elraglusib-combined-with-platinum-chemotherapy-and-sequential-immunotherapy-in-recurrent-metastatic-salivary-gland-ca/ 2025-12-15T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-phase-2-metastatic-pancreatic-cancer-data-selected-for-oral-and-poster-presentation-at-asco-gi-2026/ 2025-12-18T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-positive-patient-outcomes-from-phase-1-trial-in-difficult-to-treat-refractory-pediatric-cancers/ 2026-01-06T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-reports-positive-follow-up-data-from-its-randomized-controlled-phase-2-trial-demonstrating-extended-long-term-overall-survival-benefit-with-elraglusib-plus-chemotherapy-for-metast/ 2026-01-12T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-plans-to-expand-clinical-pipeline-advancing-elraglusib-tablet-into-a-phase-1-2-clinical-program-in-refractory-cancers/ 2026-01-21T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference/ 2026-02-24T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-present-at-the-citizens-life-sciences-conference/ 2026-03-04T05:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-launches-strategic-research-initiative-to-combine-elraglusib-with-ras-inhibitors/ 2026-03-09T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-nature-medicine-publication-of-clinical-trial-results-showing-doubling-of-the-rate-of-survival-with-elraglusib-plus-chemotherapy-in-previously-untreated-metastatic-pancr/ 2026-04-14T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-key-appointment-of-industry-veteran-to-board-of-directors/ 2026-05-06T08:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-fda-clearance-of-ind-for-oral-elraglusib-and-strategic-initiatives-to-advance-the-elraglusib-development-program/ 2026-05-11T07:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-asco-poster-presentations-demonstrating-compelling-clinical-and-biomarker-data-for-elraglusib-in-first-line-metastatic-pancreatic-cancer/ 2026-06-02T12:20:59+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-elraglusib-selected-for-evaluation-in-beacon2-trial-for-high-risk-pediatric-neuroblastoma/ 2026-06-09T07:45:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference/ 2026-09-09T05:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-announces-promising-preclinical-data-showing-synergistic-activity-of-elraglusib-in-combination-with-ras-inhibitors-zoldonrasib-and-daraxonrasib/ 2026-09-09T07:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-announces-pricing-of-11-0-million-underwritten-public-offering/ 2026-10-27T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-receives-u-s-notice-of-allowance-for-patent-covering-elraglusib-oral-tablets/ 2026-11-02T08:00:00+00:00 https://actuatetherapeutics.com/press_releases/actuate-therapeutics-to-present-promising-preclinical-data-demonstrating-antitumor-and-immune-activation-activity-of-elraglusib-oral-tablet-in-advanced-melanoma-models-at-ena-2026/ 2026-11-04T08:00:00+00:00